Book contents
- Common Pitfalls in Multiple Sclerosis and CNS Demyelinating DiseasesCase-Based Learning
- Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases
- Copyright page
- Contents
- Preface
- Chapter 1 Pitfalls in identifying the classical clinical features of MS
- Chapter 2 Pitfalls in correctly assessing the clinical course of MS
- Chapter 3 Pitfalls in recognizing uncommon MS clinical presentations
- Chapter 4 Challenges in the therapeutic management of MS
- Chapter 5 Challenges in diagnosing demyelinating ocular disease
- Chapter 6 Pitfalls in diagnosing cerebral parenchymal disease
- Chapter 7 Pitfalls in diagnosing demyelinating cerebellar disease
- Chapter 8 Challenges in diagnosing demyelinating brainstem disease
- Chapter 9 Challenges in diagnosing spinal cord disease
- Index
- References
Chapter 4 - Challenges in the therapeutic management of MS
Published online by Cambridge University Press: 05 May 2016
Book contents
- Common Pitfalls in Multiple Sclerosis and CNS Demyelinating DiseasesCase-Based Learning
- Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases
- Copyright page
- Contents
- Preface
- Chapter 1 Pitfalls in identifying the classical clinical features of MS
- Chapter 2 Pitfalls in correctly assessing the clinical course of MS
- Chapter 3 Pitfalls in recognizing uncommon MS clinical presentations
- Chapter 4 Challenges in the therapeutic management of MS
- Chapter 5 Challenges in diagnosing demyelinating ocular disease
- Chapter 6 Pitfalls in diagnosing cerebral parenchymal disease
- Chapter 7 Pitfalls in diagnosing demyelinating cerebellar disease
- Chapter 8 Challenges in diagnosing demyelinating brainstem disease
- Chapter 9 Challenges in diagnosing spinal cord disease
- Index
- References
- Type
- Chapter
- Information
- Common Pitfalls in Multiple Sclerosis and CNS Demyelinating DiseasesCase-Based Learning, pp. 30 - 39Publisher: Cambridge University PressPrint publication year: 2016
References
Further reading
Fox, RJ, Miller, DH, Phillips, JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. The New England Journal of Medicine 2012;367:1087–97.CrossRefGoogle ScholarPubMed
Pelletier, D, Hafler, DA. Fingolimod for multiple sclerosis. The New England Journal of Medicine 2012;366:339–47.CrossRefGoogle ScholarPubMed
Dorr, J, Paul, F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol 2015;17:354.CrossRefGoogle ScholarPubMed
Freedman, MS, Abdoli, M. Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. Expert Rev Neurother 2015;15:407–23.CrossRefGoogle ScholarPubMed
Goodin, DS. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin Neurol 2013;33:13–25.Google ScholarPubMed
Lublin, FD, Cofield, SS, Cutter, GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327–40.CrossRefGoogle ScholarPubMed
Willis, MA, Cohen, JA. Fingolimod therapy for multiple sclerosis. Semin Neurol 2013;33:37–44.CrossRefGoogle ScholarPubMed
Bourdette, DN, Cohen, JA. Venous angioplasty for “CCSVI” in multiple sclerosis: ending a therapeutic misadventure. Neurology 2014;83:388–9.CrossRefGoogle ScholarPubMed
Carruthers, RL, Berger, J. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice. Mult Scler Relat Disord 2014;3:419–30.CrossRefGoogle ScholarPubMed
Correale, J, Farez, MF. Smoking worsens multiple sclerosis prognosis: Two different pathways are involved. J Neuroimmunol 2015;281:23–34.CrossRefGoogle ScholarPubMed
Manouchehrinia, A, Weston, M, Tench, CR, Britton, J, Constantinescu, CS. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J Neurol Neurosurg Psychiatry 2014;85:1091–5.CrossRefGoogle ScholarPubMed
Salzer, J, Hallmans, G, Nystrom, M, Stenlund, H, Wadell, G, Sundstrom, P. Smoking as a risk factor for multiple sclerosis. Mult Scler 2013;19:1022–7.Google ScholarPubMed
Siddiqui, AH, Zivadinov, R, Benedict, RH, et al. Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology 2014;83:441–9.CrossRefGoogle ScholarPubMed
Traboulsee, AL, Knox, KB, Machan, L, et al. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. Lancet 2014;383:138–45.CrossRefGoogle ScholarPubMed
Tur, C, Montalban, X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 2014;28:641–8.CrossRefGoogle ScholarPubMed
Wingerchuk, DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord 2012;5:13–22.CrossRefGoogle ScholarPubMed
Xu, Z, Zhang, F, Sun, F, Gu, K, Dong, S, He, D. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev 2015;4:CD011076.Google Scholar